Proactiveinvestors recommends
Stocktube video
09/11/2011

e-Therapeutics CFO says 2012 will be an exciting year for the company

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: ETX
Latest Price: 38.00p  (-1.30% Descending)
52-week High: 46.50p
52-week Low: 25.00p
Market Cap: 52.49M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
e-Therapeutics plc
www.etherapeutics.co.uk

 

e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.  

It has a clinical pipeline of four drugs set to enter clinical trials during 2012. The Company is listed on AIM with the ticker symbol ETX.

 

Full e-Therapeutics plc profile here
Is ETX a Buy, Sell or Hold?Get your FREE analysis of ETX
Pdf

e-Therapeutics bolsters board ahead of clinical trials

6th Feb 2012, 8:54 am by Giles Gwinnett Oliver James, chairman of e-Therapeutics, said the appointment represented a further significant strengthening of the board

e-Therapeutics (LON:ETX) has bolstered its board with the appointment of a drug discovery expert.

Dr Rajesh Chopra has joined the company as a non-executive director, it said today.

Since 2009, Dr Chopra has been vice president at Celgene Corporation and leads 100 people in their work to integrate drug discovery and clinical development at Celgene sites in the USA and Spain.

Before joining Celgene, he spent five years at AstraZeneca and was also previously clinical director of the department of haematological oncology at the Christie Hospital, Manchester.

Oliver James, chairman of e-Therapeutics, said the appointment represented a further significant strengthening of the board.

"He (Dr Chopra) brings highly relevant senior-level experience gained in world-leading pharma and biotech companies and substantial expertise in oncology.

"His input will be of great value as we advance our clinical programmes and bring more new drugs through into development from our discovery operation.”

Meanwhile, Dr Chopra added that he was delighted at his appointment: “e-Therapeutics is the world leader in network pharmacology, which is turning out to be a fascinating, highly distinctive and influential approach to drug discovery," he said.

Last month, the company said it was looking forward to an important 2012 year - as it advances four of its drugs into clinical trials.

Anti-cancer drug ETS2101 will undergo a phase 1 programme beginning in the first quarter of this year. In Q2, the phase 1 trial for ETX1153c concerning C. difficile infection will begin.

A phase IIb trial for anti-depressant ETS6103 will begin in the third quarter, while, for MRSA, the phase 1 trial for ETX1153a will start in the fourth quarter, the company told investors.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.